Sionna Therapeutics, Inc. (SION) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Core Insights - The company, Sionna, is focused on developing treatments for cystic fibrosis (CF) by targeting a differentiated and previously considered undruggable target known as NBD1 [3] Company Overview - Sionna aims to transform the standard of care in cystic fibrosis, with NBD1 as the central element of its strategy [3] - The company has recently initiated a Phase IIa proof-of-concept study for its NBD1 stabilizer, SION-719, which will be tested in conjunction with TRIKAFTA, the current standard of care [4]